Literature DB >> 17425686

Clearance mechanisms of von Willebrand factor and factor VIII.

P J Lenting1, C J M VAN Schooten, C V Denis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17425686     DOI： 10.1111/j.1538-7836.2007.02572.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  40 in total

1.  von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.

Authors:  Nicoletta Sorvillo; Robin B Hartholt; Esther Bloem; Magdalena Sedek; Anja ten Brinke; Carmen van der Zwaan; Floris P van Alphen; Alexander B Meijer; Jan Voorberg
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

2.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

Review 3.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

4.  Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.

Authors:  Julie N Pegon; Mohamad Kurdi; Caterina Casari; Soline Odouard; Cécile V Denis; Olivier D Christophe; Peter J Lenting
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

5.  Von Willebrand factor protects against acute CCl4-induced hepatotoxicity through phospho-p38 MAPK signaling pathway inhibition.

Authors:  Hai-Jian Sun; Jian Chen; Hao Zhang; Bing Ni; Jennifer C van Velkinburgh; Yao Liu; Yu-Zhang Wu; Xia Yang
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

6.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

7.  Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.

Authors:  A Gézsi; U Budde; I Deák; E Nagy; A Mohl; A Schlammadinger; Z Boda; T Masszi; J E Sadler; I Bodó
Journal:  J Thromb Haemost       Date:  2010-01-17       Impact factor: 5.824

8.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

9.  The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

Authors:  Natalia Rydz; Laura L Swystun; Colleen Notley; Andrew D Paterson; J Jacob Riches; Kate Sponagle; Boonchai Boonyawat; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  Blood       Date:  2013-03-25       Impact factor: 22.113

10.  Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.

Authors:  Kathelijn Fischer; Ronan Pendu; Carina J van Schooten; Karin van Dijk; Cécile V Denis; H Marijke van den Berg; Peter J Lenting
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.